Your browser doesn't support javascript.
loading
Expert consensus on safety management of bone-modifying agents / 中华肿瘤杂志
Chinese Journal of Oncology ; (12): 622-628, 2021.
Article in Chinese | WPRIM | ID: wpr-887466
ABSTRACT
Bone-modifying agents currently include bisphosphonates and desumumab, which are the main drugs for the treatment of malignant tumor bone metastasis, hypercalcemia and osteoporosis. Due to its wide clinical application, the adverse events of this kind of drugs are gradually increasing and affecting the quality of life of patients. Therefore, it needs to arouse the attention of the majority of medical personnel. Based on the substantial evidence, the expert committee has thoroughly discussed the management of adverse reactions of bone modifying agents and put forward reasonable suggestions, to guide clinicians in the safety management of such drugs.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Osteoporosis / Quality of Life / Safety Management / Consensus / Diphosphonates / Bone Density Conservation Agents Type of study: Practice guideline Limits: Humans Language: Chinese Journal: Chinese Journal of Oncology Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Osteoporosis / Quality of Life / Safety Management / Consensus / Diphosphonates / Bone Density Conservation Agents Type of study: Practice guideline Limits: Humans Language: Chinese Journal: Chinese Journal of Oncology Year: 2021 Type: Article